Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks
The MPXV CARE study principally aims to use clinical and epidemiology data to target specific individuals willing and able to provide appropriate and proportionate biological samples to develop novel immune diagnostics that support models of disease burden and future vaccine utilisation.
| Condition(s) | Mpox |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The MPXV CARE study principally aims to use clinical and epidemiology data to target specific individuals willing and able to provide appropriate and proportionate biological samples to develop novel immune diagnostics that support models of disease burden and future vaccine utilisation. |
| Who can participate | Inclusion Criteria: * Healthy males and females aged between ages 5-80 years, who are able and willing to provide informed consent and will comply with the study requirements. * Group 1 (suspected exposure cohort) only * Live within or adjacent to an epidemiologically identified region of Mpox transmission * Close contacts of those with microbiologically confirmed Mpox * Group 2 (post-exposure/vaccinated cohort) only * Previous clinically or microbiologically confirmed Mpox or confirmed previous vaccination with a smallpox/MVA vaccine * Fully recovered from Mpox infection * Group 3 (control cohort) only: * Asymptomatic with no known exposure to Mpox Exclusion Criteria: * Unwilling or unable to provide informed consent to take part * Unwilling or unable to comply with study procedures * His |
| Ages | 5 Years to 80 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | University of Birmingham |
| Locations | Kigali, Rwanda |
| Start date | 2025-02-05 |
| NCT ID | NCT06887556 |
| Official listing | https://clinicaltrials.gov/study/NCT06887556 |